Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Interest Expenses (2020 - 2022)

Vivos Therapeutics (VVOS) has disclosed Interest Expenses for 3 consecutive years, with $36000.0 as the latest value for Q3 2022.

  • On a quarterly basis, Interest Expenses rose 279.43% to $36000.0 in Q3 2022 year-over-year; TTM through Jun 2023 was $36000.0, a 59.32% decrease, with the full-year FY2021 number at $14000.0, down 85.42% from a year prior.
  • Interest Expenses was $36000.0 for Q3 2022 at Vivos Therapeutics, down from $37000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $43723.0 in Q1 2020 to a low of $1000.0 in Q1 2021.
  • A 3-year average of $20226.2 and a median of $17218.0 in 2020 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: plummeted 97.71% in 2021, then soared 3700.0% in 2022.
  • Vivos Therapeutics' Interest Expenses stood at $17218.0 in 2020, then tumbled by 76.77% to $4000.0 in 2021, then surged by 800.0% to $36000.0 in 2022.
  • Per Business Quant, the three most recent readings for VVOS's Interest Expenses are $36000.0 (Q3 2022), $37000.0 (Q2 2022), and $38000.0 (Q1 2022).